#AbbVie

Accessing new hepatitis C treatments is a problem for patients, even with drugs at reduced costs

The Food and Drug Administration (FDA) recently approved AbbVie’s Mavyret, the newest treatment for chronic hepatitis C.

The two-drug regimen can cure the virus in as little as eight weeks.

A promising new regimen that will address unmet needs for this population is poised for FDA approval.

Maviret and Vosevi were highly effective and well tolerated in clinical trials.

Highlights from research presented at the 52nd International Liver Congress in Amsterdam

In an analysis of the investigational treatment, cure rates were very high for those without cirrhosis after both 8 and 12 weeks of therapy.

The recent trial of glecaprevir/pibrentasvir included those with genotypes 1, 2, 4, 5 and 6 of hep C who had compensated cirrhosis.

Glecaprevir/pibrentasvir (G/P) cured high rates of those with genotype 1 who failed a previous hep C cure attempt in a Phase II study.

This Hep story shows the power of never giving up, and the transformation that comes as a result.

The single-pill regimen would provide an eight-week ribavirin-free option for those with all viral genotypes who do not have cirrhosis.

The once-daily investigational hepatitis C virus (HCV) combination tablet will likely be approved in 2017.

The investigational glecaprevir/pibrentasvir performed very well among the historically hard-to-treat group, including those with cirrhosis.

AbbVie’s investigational hepatitis C virus (HCV) treatment is poised for approval in 2017.